Zevra Therapeutics (ZVRA) Asset Writedowns and Impairment (2024 - 2026)

Zevra Therapeutics (ZVRA) has 3 years of Asset Writedowns and Impairment data on file, last reported at $485000.0 in Q1 2026.

• Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $485000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.2 million (up 2567.98% YoY) and the FY2025 annual result came in at $11.7 million, up 104.93% from the prior year.
• Asset Writedowns and Impairment grew to $485000.0 in Q1 2026, from -$19000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $11.7 million in Q2 2025 to a low of -$19000.0 in Q4 2025.
• A 3-year average of $3.2 million and a median of $470500.0 in 2024 frame the typical range for Asset Writedowns and Impairment.
• The widest YoY moves for Asset Writedowns and Impairment: up 104.17% in 2025, down 104.17% in 2025.
• Tracing ZVRA's Asset Writedowns and Impairment over 3 years: stood at $456000.0 in 2024, then sank by 104.17% to -$19000.0 in 2025, then jumped by 2652.63% to $485000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $485000.0 (Q1 2026), -$19000.0 (Q4 2025), and $11.7 million (Q2 2025), per Business Quant data.